A randomized, double-blind, placebo controlled, parallel group, efficacy study of alpha BRAIN® administered orally

ObjectiveAlpha BRAIN (R) is a nootropic supplement that purports to enhance cognitive functioning in healthy adults. The goal of this study was to investigate the efficacy of this self-described cognitive enhancing nootropic on cognitive functioning in a group of healthy adults by utilizing a randomized, double blind, placebo-controlled design. MethodsA total of 63-treatment naive individuals between 18 and 35years of age completed the randomized, double-blind, placebo controlled trial. All participants completed a 2-week placebo run in before receiving active product, Alpha BRAIN (R) or new placebo, for 6weeks. Participants undertook a battery of neuropsychological tests at randomization and at study completion. Primary outcome measures included a battery of neuropsychological tests and measures of sleep. ResultsCompared with placebo, Alpha BRAIN (R) significantly improved on tasks of delayed verbal recall and executive functioning. Results also indicated significant time-by-group interaction in delayed verbal recall for the Alpha BRAIN (R) group. ConclusionsThe use of Alpha BRAIN (R) for 6weeks significantly improved recent verbal memory when compared with controls, in a group of healthy adults. While the outcome of the study is encouraging, this is the first randomized controlled trial of Alpha BRAIN (R), and the results merit further study.